

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Arylacetamide deacetylase-like 1 (AADACL1; KIAA1363)	An <i>in vitro</i> and mouse study identified an inhibitor of KIAA1363 that may help treat prostate cancer. In a prostate cancer cell line, the lead <i>O</i> -aryl carbamate inhibitor JW480 blocked KIAA1363 with an IC ₅₀ value of 12 nM and led to lower invasion, migration and survival than vehicle. In a mouse xenograft model of prostate cancer, JW480 decreased tumor growth compared with vehicle. Next steps include testing the inhibitor plus other agents in models of prostate cancer metastasis and in other cancers that show KIAA1363 overexpression.	Patent applications filed; licensing status undisclosed	Chang, J.W. <i>et al. Chem. Biol.</i> ; published online April 22, 2011; doi:10.1016/j.chembiol.2011.02.008 Contact: Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, Calif. e-mail: cravatt@scripps.edu
SciBX 4(18); doi:10.1038/scibx.2011.511 Published online May 5, 2011				